2023 was another year of significant progress in the fight against HIV, tuberculosis (TB) and malaria. In countries where the Global
Fund invests, there has been a full recovery from the disruptive impact of the COVID-19 pandemic. The results we have achieved in the last year build on our extraord...inary track record of progress. Over the last two decades, our partnership has cut the combined death rate from AIDS, TB and malaria by 61%. As of the end of 2023, the Global Fund partnership has saved 65 million lives.
more
Poverty and associated health, nutrition, and social factors prevent at least 200 million children in developing countries from attaining their developmental potential. We review the evidence linking compromised development with modifiable biological and psychosocial risks encountered by children fr...om birth to 5 years of age. We identify four key risk factors where the need for intervention is urgent: stunting, inadequate cognitive stimulation, iodine deficiency, and iron deficiency anaemia. The evidence is also sufficient to warrant interventions for malaria, intrauterine growth restriction, maternal depression, exposure to violence, and exposure to heavy metals. We discuss the research needed to clarify the effect of other potential risk factors on child development. The prevalence of the risk factors and their effect on development and human potential are substantial. Furthermore, risks often occur together or cumulatively, with concomitant increased adverse effects on the development of the world's poorest children.
more
The eEML is a comprehensive, freely accessible online database containing information on essential medicine
To mark the International Day of the African Child, Medicines for Malaria Venture (MMV) celebrated the inclusion of three of its antimalarial medicines on the WHO Model List of Essential Medicines (EML) and the EML for Children (EMLc). These are two artemisinin-based combination therapies (ACTs) for... adults, children and infants, and a rectal artesunate formulation for the pre-referral treatment of severe malaria in young children. The approved therapies — pyronaridine–artesunate, dihydroartemisinin–piperaquine and rectal artesunate — offer child-friendly formulations and are the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum and P. vivax. Inclusion in the EMLc facilitates national adoption, improves access to high-quality treatments and addresses the disproportionate malaria burden among children under five. This supports global efforts to reduce malaria mortality and advance elimination.
more
Soumis à l’Agence des États-Unis pour le développement international par le programme SIAPS (Systems for Improved Access to Pharmaceuticals and Services ou Programme des systèmes pour l’amélioration de l’accès aux produits et services pharmaceutiques). Arlington, VA : Management Sciences... for Health. Soumis à l’UNICEF par JSI, Arlington, VA : JSI Research & Training Institute, Inc.
Ce guide aidera les gestionnaires de programmes, les prestataires de service et les experts techniques lorsqu'ils réaliseront une quantification des besoins en intrants pour les 13 produits indispensables à la santé reproductive, maternelle, néonatale et infantile, dont la priorité a été établie par la Commission des Nations Unies pour les produits qui sauvent la vie des femmes et des enfants. Ce supplément à la quantification ne saurait être utilisé sans son guide principal – Quantification of Health Commodities: A Guide to Forecasting and Supply Planning for Procurement (Quantification des intrants de santé : un guide pour la prévision des achats et la planification des approvisionnements). * Ce supplément décrit les étapes à suivre pour la prévision de la consommation de ces intrants, en l’absence de données sur la consommation ou les services. Ensuite, afin de compléter la quantification, les utilisateurs doivent se référer au guide principal de quantification pour l’étape de planification de l’approvisionnement.
more